Clinical Test Validates Precision Medicine for Cancer

“Much of precision medicine and cancer care focuses on targeting the genomes of specific tumors or metastases. A Weill Cornell Medical College research team has now shown that a more global look at the body using next-generation sequencing can offer new insights and treatment targets in patients with advanced, treatment-resistant disease.

“The research, published May 28 in JAMA Oncology, offers a look at how the Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian Hospital is transforming the way physician-scientists address individualized cancer care.

” ‘Most institutions are using focused or panel sequencing to look at a few hot spot mutation areas in cancer,’ said senior author Dr. Mark Rubin, the institute’s director, and the Homer T. Hirst III Professor of Oncology in Pathology and a professor of pathology and laboratory medicine at Weill Cornell. ‘But we believe that Whole Exome Sequencing, which tests more than 21,000 genes in the cancer’s exome, the DNA that is transcribed into RNA, is ideal for patients with advanced cancer where we don’t know where the mutations of resistance are.’ “